findmyKOL
Clinical trialNCT03443856UnknownPhase 2Interventional

Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence

SponsorEuropean Organisation for Research and Treatment of Cancer - EORTCEnrollment197Gastric and Esophagogastric Junction Adenocarcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Elizabeth Smyth

    Cambridge University Hospital NHS - Cambridge, UK

    Study Chair
  • Florian Lordick

    Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig, Germany

    Study Chair
  • Maren Knoedler

    Universitaetsklinikum Leipzig-Ambulanzen/Sprechstunden, Leipzig, Germany

    Study Chair

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

28 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Czechia
  • Masaryk Memorial Cancer Institute

    Brno, Czechia

  • University Hospital Hradec Kralove

    Hradec Králové, Czechia

France
  • Chru de Lille - Hopital Huriez

    Lille, France

  • Hôpital Privé Jean Mermoz

    Lyon, France

  • Gustave Roussy

    Villejuif, France

Germany
  • Charite - Universitaetsmedizin Berlin

    Berlin, Germany

  • Kliniken Essen-Mitte

    Essen, Germany

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf Ke - University Cancer Center

    Hamburg, Germany

  • Slk-Kliniken Heilbronn

    Heilbronn, Germany

  • Universitaetsklinikum Leipzig-Ambulanzen/sprechstunden

    Leipzig, Germany

  • Klinikum Rechts Der Isar Der Technische Universitaet Muenchen - Klinikum Rechts Der Isar

    München, Germany

  • Universitaetsklinikum Tuebingen-Uni Kliniken Berg

    Tübingen, Germany

Israel
  • Rambam Health Care Campus, Oncology Institute

    Haifa, Israel

  • Rabbin Medical Centre - Tel Aviv

    Tel Aviv, Israel

Italy
  • Azienda Ospedaliera A Papa Giovanni Xxiii

    Bergamo, Italy

  • Istituto Europeo Di Oncologia

    Milan, Italy

  • Istituto Nazionale Tumori Irccs "fondazione G. Pascale"

    Naples, Italy

Norway
  • Oslo University Hospital - Ullevaal Hospital

    Oslo, Norway

Poland
  • Maria Sklodowska-Curie Memorial Cancer Centre

    Warsaw, Poland

Spain
  • Institut Catalan D'Oncologia - Ico Badalona

    Badalona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Complejo Hospitalario A

    Pamplona, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

United Kingdom
  • Cambridge University Hospital Nhs

    Cambridge, United Kingdom

  • Royal Marsden Hospital

    London, United Kingdom

  • University College London Hospitals Nhs Foundation Trust

    London, United Kingdom

  • Royal Marsden Hospital

    Sutton, United Kingdom

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Jul 2019
Primary completion
12 Dec 2023
Completion
30 Jun 2026
Last update posted
5 Jan 2024
Registered enrollment
197
Registry id
NCT03443856

Cross-registrations

EU-CTR / CTIS (EudraCT)2018-000406-36

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.